JW Life Science acquires commercialization approval of epilepsy therapy ‘Levetiram’
A new-concept solution, which relieve seizure for epilepsy patients, will be released in Korea.
JW Life Science(CEO Sung-Nam Cha) announced on the 12th that it has acquired commercialization approval of ‘Levetiram Inj 1,000mg,’ an epilepsy therapy, from the Ministry of Food and Drug Safety(MFDS)...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
